Clinical trials: Thyroid Cancer Patients
Differentiated Thyroid Cancer
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with Donafenib 0.3g Bid by continuous oral…
- Trial name
- DTC (NCT03602495)
- Testing
- Donafenib
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Differentiated Thyroid Cancer
A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.
This trial is a prospective, non-interventional, monocentric study aiming to collect standard of care imaging of patients treated with Iodine-131 for the determination of dosimetric studies.
- Trial name
- MEDIRAD (NCT03986437)
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Claudius Regaud
Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
This clinical trial evaluates the impact of a patient-centered health and wellness coaching (HWC) intervention on adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid…
- Trial name
- NCT07545837
- Testing
- Counseling, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Hypothyroidism, Brain Tumor
Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors
Primary Objectives: 1. Assess whether combined treatment with Levothyroxine and Liothyronine improves learning and memory. 2. Explore the relationship between T3 treatment and other domains of cognitive function, quality of life…
- Trial name
- NCT00488644
- Testing
- Levothyroxine, Liothyronine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors, Thyroid Cancer
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
- Conditions
- Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
- Trial name
- NCT01438554
- Testing
- Pazopanib, GSK1120212
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumor and Hematologic Malignancies
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT01885195)
- Testing
- MEK162
- Where
- 68 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Thyroid Nodules, Thyroid Cancer
AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid
There is an epidemic of thyroid cancer that is harmful to patients and the medical system. The study hypothesizes that the use of an electronic conversation aid during clinical visits can help patients and clinicians collaborate.
- Trial name
- NCT04463719
- Testing
- Counseling using the electronic conversation aid, counseling by routine care
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- University of Florida
Thyroid Carcinoma, Dyslipidemias
Lipid Metabolic Status in Thyroid Carcinoma
The continuous increase of the incidence of the thyroid cancer in the last years has taken this neoplasia among the first 4 frequent cancers in the cancer registry of the Institute of Oncology "Prof.Ion Chiricuţă" from…
- Conditions
- Thyroid Carcinoma, Dyslipidemias, Risk Reduction Behavior, Hormone Replacement
- Trial name
- LITCA (NCT01487057)
- Where
- Romania
- Volunteers
- 52 people
- Sponsor
- Prof. Dr. I. Chiricuta Institute of Oncology
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.
- Conditions
- Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
- Trial name
- DUTHY (NCT03753919)
- Testing
- Durvalumab, Tremelimumab
- Where
- 15 sites in Spain
- Volunteers
- 79 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy
Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer
Background: Papillary thyroid cancer (PTC) often spreads to lymph nodes in the neck. This can be hard to detect. People often have lymph nodes removed anyway, and researchers want to study if this is a good idea.
- Conditions
- Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer
- Trial name
- NCT02408887
- Testing
- Total Thyroidectomy (TT), Prophylactic central neck lymph node dissection (pCND)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasms, Lung Neoplasms
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity.
- Conditions
- Brain Neoplasms, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms
- Trial name
- NCT00123760
- Testing
- Positron Emission Tomography (PET) scan
- Where
- Canada
- Volunteers
- 10,838 people
- Sponsor
- AHS Cancer Control Alberta
Thyroid Cancer
Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System
The aim of the study is to evaluate differences between use of Ultrasonic Coagulation Device (New Harmonic ACE™, Ethicon endo-surgery) and Bipolar Energy Sealing System (LigaSure Precise™, Covidien) in surgery for thyroid cancer.
- Trial name
- UCBEST (NCT01565486)
- Testing
- Ultrasonic coagulation device (Harmonic ACE® scalpel), bipolar energy sealing system (LigaSure Precise)
- Where
- South Korea
- Volunteers
- 304 people
- Sponsor
- Seoul St. Mary's Hospital
Maligant Solid Tumor, Head & Neck Cancer
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Conditions
- Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
- Trial name
- NCT07459283
- Testing
- INN805
- Where
- China
- Volunteers
- 10 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
Increased fibroblast activation protein expression is positively correlated with the dedifferentiation and aggressiveness of thyroid cancer.
- Conditions
- Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma
- Trial name
- NCT05410821
- Testing
- 177Lu-DOTA-EB-FAPI 1 radionuclide therapy, 177Lu-DOTA-EB-FAPI 2 radionuclide therapy, 177Lu-DOTA-EB-FAPI 3 radionuclide therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Cognitive Impairment
Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma
Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 90% thyroid carcinoma is thyroid differentiated carcinoma（DTC）.
- Trial name
- NCT02665325
- Testing
- TSH-suppressive therapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Inner Mongolia Medical University
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
This phase II trial studies how well pembrolizumab, chemotherapy, and radiation therapy work with or without surgery in treating patients with anaplastic thyroid cancer.
- Trial name
- NCT03211117
- Testing
- Docetaxel, Doxorubicin Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Thyroid Neoplasms
Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients
A retrospective analysis was conducted on patients with radioiodine-refractory thyroid carcinoma (RRTC) who underwent radioactive 125I seed implantation combined with anlotinib from January 2019 to October 2024 at Jiangxi Cancer…
- Trial name
- NCT06367010
- Testing
- Iodine-125 brachytherapy combine with Anlotinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Jiangxi Provincial Cancer Hospital